Last reviewed · How we verify
Servier (Tianjin) Pharmaceutical Co. LTD. — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Biosynthetic Human Insulin Injection | Biosynthetic Human Insulin Injection | marketed | ||||
| Gliclazide MR and Insulin Glargine Injection | Gliclazide MR and Insulin Glargine Injection | marketed |
Therapeutic area mix
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Servier (Tianjin) Pharmaceutical Co. LTD.:
- Servier (Tianjin) Pharmaceutical Co. LTD. pipeline updates — RSS
- Servier (Tianjin) Pharmaceutical Co. LTD. pipeline updates — Atom
- Servier (Tianjin) Pharmaceutical Co. LTD. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Servier (Tianjin) Pharmaceutical Co. LTD. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/servier-tianjin-pharmaceutical-co-ltd. Accessed 2026-05-16.